Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy

Wei Xin; Xie YuMei; Chen Lin; Pan Lei; Hao ChunQiu; Wang JiuPing; Bai XueFan; Jia ZhanSheng

Issue 1

Jan. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(1): 89-92

PDF( 2118 KB)

Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy

Research funding:

Published Date: 2011-01-20

Abstract

Abstract

Objective To investigate the clinical efficacy of antiviral therapy in patients with HCV related cirrhosis and to establish the grading of standard antiviral therapy for these patients.Methods 82 patients diagnosed with HCV related cirrhosis were included in this study,and were divided into 3 groups depending on the degree of cirrhosis,hypersplenism and the tolerance of treatment.After treating with hematopoietic growth factors,partial splenic embolization or splenectomy,the improvement of hypersplenism was observed.Based on the standard antiviral therapy,more active response guided therapy were used to achieve more ideal effect.The effect of treatment and the liver function were analyzed.32 patients with chronic hepatitis C were studied as control.Results The count of white blood cells and platelets were increased significantly.The EVR rate of partial splenic embolization and splenectomy were about 60%,and the SVR rate were 59.3% and 63.6% respectively.The levels of ALT were decreased significantly.Conclusion We propose the grading strategy of antiviral therapy for patients with HCV related cirrhosis,which could slow down the rate of progression of the cirrhosis and improve the quality of life.
- liver cirrhosis,
- hepacivirus,
- interferon alfa-2a,
- Ribavirin,
- antiviral agents

FullText(HTML)

References(9)

References

[1]Perz JF,Farrington LA,Pecoraro C,et al.Estimated global prevalence of hepatitis C virus[R].42nd Annual Meeting of the Infection Disease Society of America.2004 Sept 30-Oct 3;Boston,MA,USA.

[2]中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志,2004,12(4):194-198.

[3]Forns X,Navasa M,Rodes J.Treatment of HCV infection in patients with advanced cirrhosis[J].Hepatology,2004,40(2):498.

[4]Danish FA,Koul SS,Subhani FR,et al.Antiviral therapy in HCV-infected decompensated cirrhotics[J].Saudi J Gastroenterol,2010,16(4):310-314.

[5]Ohkoshi S,Yamagiwa S,Yano M,et al.Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C:A Possible Therapeutic Alternative without Splenic Intervention[J].Case Rep Gastroenterol,2010,4(2):261-266.

[6]Ghany MG,Strader DB,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C:an update[J].Hepatology,2009,49(4):1335-1374.

[7]von Hahn T,Steinmann E,Ciesek S,et al.Know your enemy:translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches[J].Expert Rev Gastroenterol Hepatol,2010,4(1):63-79.

[8]Reichen J.ACP Journal Club.Telaprevir combination therapy induced a sustained virologic response in nonresponsive chronic HCV infection[J].Ann Intern Med,2010,153(4):JC2-7.

[9]Mederacke I,Wedemeyer H,Manns MP.Boceprevir,an NS3 serine protease inhibitor of hepatitis C virus,for the treatment of HCV infection[J].Curr Opin Investig Drugs,2009,10(2):181-189.

Relative Articles

[1]	LIU YuWei, JIN JingLan, REN TianYi, GAO XiuZhu, LI Jie, ZHU Qing, NIU JunQi. Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2714-2719. doi: 10.3969/j.issn.1001-5256.2020.12.015
[2]	Zhang YaoDi, Zhang YueRong, Wang Hui, Lin Yan, Zhou Ning, Wu LiYang, Wei ShiFang, Li XiangLin. Clinical features of hepatitis C patients with failure or recurrence after treatment with pegylated interferon-α combined with ribavirin and the clinical effect of direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2019, 35(11): 2456-2460. doi: 10.3969/j.issn.1001-5256.2019.11.014
[3]	You GuoQiong, Wang Li, Duan Meng, Zhu Peng. Research advances in direct-acting antiviral agents in the treatment of hepatitis C virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 187-190. doi: 10.3969/j.issn.1001-5256.2019.01.041
[4]	Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
[5]	Yang CaiXia. Immune tolerance after drug withdrawal in a patient with chronic hepatitis B receiving PEG- IFNα- 2a treatment[J]. Journal of Clinical Hepatology, 2017, 33(1): 160-162. doi: 10.3969/j.issn.1001-5256.2017.01.035
[6]	Wu XiaoLi. Influence of combination mode of PEG-IFNα-2a and adefovir dipivoxil on outcome of patients with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2017, 33(12): 2311-2315. doi: 10.3969/j.issn.1001-5256.2017.12.011
[7]	Peng MeiJuan, Wang Wei, Yang XiaoFei, Hao ChunQiu, Bai XueFan, Jia ZhanSheng, Lian JianQi, Zhang Ye. Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 682-686. doi: 10.3969/j.issn.1001-5256.2016.04.014
[8]	Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020
[9]	Yang Long, Yang Yang, Jiang XueHua, Chen ZhiYong. Efficacy of peginterferon α- 2a in treatment of chronic hepatitis B resistant to multiple nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(4): 691-694. doi: 10.3969/j.issn.1001-5256.2016.04.016
[10]	Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
[11]	Liu YunHua, Li Zhen, Liu Li, Peng Dan, Li WeiKun, Chang LiXian, Jia Ting, Yang YongRui, Li HuiMin, Wang LiQian. Clinical study of pegylated interferon α-2a in treatment of children with HBe Ag-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(2): 193-197. doi: 10.3969/j.issn.1001-5256.2015.02.012
[12]	Liu ZhiHua, He HaiTang, Hu Jing, Fu QunXiang, Luo KangXian. Efficacy of pegylated interferon α-2a in HBe Ag-negative chronic hepatitis B patients and its influencing factors[J]. Journal of Clinical Hepatology, 2015, 31(5): 697-701. doi: 10.3969/j.issn.1001-5256.2015.05.016
[13]	Lin Wei, Si JianLin, Zhang Jian, Maimaitijiang·Wubuliaishan, Hu ZhiMing, Li DongZeng, Geng Nan. Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality[J]. Journal of Clinical Hepatology, 2015, 31(11): 1831-1836. doi: 10.3969/j.issn.1001-5256.2015.11.015
[14]	Lu JianGuo. Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(12): 922-925. doi: 10.3969/j.issn.1001-5256.2013.12.012
[15]	Zhang SuMei, Xie YuMei, Zhang Ying, Guo YongHong, Wei Xin, Jiang Na, Zhou Yun, Jia ZhanSheng. Potential of G-CSF supplementation to counter the neutrophil effects of standard PEG-IFNα plus ribavirin combination therapy for treating HCV-related cirrhosis [J]. Journal of Clinical Hepatology, 2013, 29(5): 348-351.
[16]	Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.
[17]	Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(1): 86-88.
[18]	Zhu HaiJuan, Li YongHong, Guo LiPing. One case report of hysteria in a HCV patient being treated with PEG-IFN α-2a[J]. Journal of Clinical Hepatology, 2011, 27(6): 656-657.
[19]	Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823.
[20]	Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (329) PDF downloads(261)

Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content